Diffusion Pharmaceuticals Inc Forecasted to Post Q1 2019 Earnings of ($0.90) Per Share (DFFN)

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) – Stock analysts at Zacks Investment Research issued their Q1 2019 EPS estimates for Diffusion Pharmaceuticals in a research note issued to investors on Wednesday, April 17th, Zacks Investment Research reports. Zacks Investment Research analyst D. Bautz anticipates that the company will post earnings of ($0.90) per share for the quarter. Zacks Investment Research also issued estimates for Diffusion Pharmaceuticals’ Q2 2019 earnings at ($0.90) EPS, Q3 2019 earnings at ($0.42) EPS, Q4 2019 earnings at ($0.43) EPS, FY2019 earnings at ($2.30) EPS, FY2020 earnings at ($1.39) EPS and FY2021 earnings at ($1.28) EPS.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.81) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.09.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright boosted their price target on shares of Diffusion Pharmaceuticals to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. ValuEngine lowered shares of Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.

Shares of Diffusion Pharmaceuticals stock traded down $0.10 during trading on Friday, hitting $4.30. 146,692 shares of the stock were exchanged, compared to its average volume of 844,901. Diffusion Pharmaceuticals has a 12-month low of $1.83 and a 12-month high of $11.00. The stock has a market cap of $14.87 million, a P/E ratio of -0.71 and a beta of 0.21.

A hedge fund recently bought a new stake in Diffusion Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals at the end of the most recent quarter. 5.69% of the stock is currently owned by institutional investors.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Further Reading: What is a Tariff?

Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.